Interleukin-13 neutralization modulates interleukin-13 induced suppression of reactive oxygen species production in peritoneal macrophages in a murine T-cell lymphoma.
IL-13 is a Th2 cytokine that regulates the effector functions and alters the phenotype and function of normal macrophages switching to alternatively activated or type II polarized macrophages. The type II polarized macrophages differ from normal macrophages greatly in terms of receptor expression, NO and other cytokine production. It produces chemokines that preferentially attract Th2 cells, which increases the local concentration of Th2 cytokines including IL-13. As a result, normal macrophage population gets polarized as type II macrophages at the site of the tumor-microenvironment. In the present investigation, we have determined the IL-13 serum level in DL-bearing host and the effect of IL-13 on peritoneal macrophages harvested from normal healthy, control DL-bearing, and treated DL-bearing mice with respect to reactive oxygen intermediate production. It has been observed that IL-13 significantly inhibits the ROI generation in all macrophage types while by neutralizing with invivo administration of IL-13R*2 and/or potentiation with Th1 cytokine, the production of reactive oxygen intermediate increases, which indicates that IL-13R*2 and/or potentiation with Th1 cytokine could restore the cytotoxic ability of macrophage in a murine T-cell lymphoma.
Deepak
Praveen
P
Immunology Laboratory, CAS in Zoology, Banaras Hindu University, Lanka, Varanasi 221 005, Uttar Pradesh, India.
Kumar
Sanjay
S
Acharya
Arbind
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006861:Hydrogen Peroxide / Q000037:antagonists & inhibitors / Q000378:metabolism; D007371:Interferon-gamma / Q000276:immunology / Q000494:pharmacology; D018793:Interleukin-13 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology / Q000494:pharmacology*; D053661:Interleukin-13 Receptor alpha1 Subunit / Q000276:immunology; D008070:Lipopolysaccharides / Q000494:pharmacology; D016399:Lymphoma, T-Cell / Q000097:blood / Q000276:immunology*; D008262:Macrophage Activation / Q000187:drug effects / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D017382:Reactive Oxygen Species / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms
D000911:Antibodies, Monoclonal; D018793:Interleukin-13; D053661:Interleukin-13 Receptor alpha1 Subunit; D008070:Lipopolysaccharides; D017382:Reactive Oxygen Species; D011994:Recombinant Proteins; D007371:Interferon-gamma; D006861:Hydrogen Peroxide